PUNE, India, November 14, 2016 /PRNewswire/ --
ReportsnReports.com adds "Idiopathic Pulmonary Fibrosis - PipelineReview, H2 2016" to its store providing comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of
Complete report on H2 2016 pipeline review of Idiopathic Pulmonary Fibrosis with 78 market data tables and 15 figures, spread across 260 pages is available at http://www.reportsnreports.com/reports/743476-idiopathic-pulmonary-fibrosis-pipeline-review-h2-2016.html .
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.
Companies discussed in this Idiopathic Pulmonary Fibrosis Pipeline Review, H2 2016 report include AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., Afferent Pharmaceuticals, Inc., Apellis Pharmaceuticals Inc, ARMO Biosciences, Inc., Asahi Kasei Pharma Corp., Biogen Inc, Bioneer Corporation, BiOrion Technologies B.V., Bristol-Myers Squibb Company, Celgene Corporation, Chrysalis Pharma SAS, Compugen Ltd., Cynata Therapeutics Limited, F. Hoffmann-La Roche Ltd., FibroGen, Inc., FibroStatin SL, Galapagos NV, GenKyoTex S.A., GlaxoSmithKline Plc, Global Blood Therapeutics, Inc., GNI Group Ltd., HEC Pharm Co., Ltd., Histocell S.L., iBio, Inc., Immunomet Therapeutics, Inc., Inventiva, Isarna Therapeutics GmbH, Kadmon Corporation, LLC, Kasiak Research Private Limited, Kolltan Pharmaceuticals, Inc., Kyorin Pharmaceutical Co., Ltd., Lung Therapeutics Inc, Moerae Matrix, Inc., MorphoSys AG, Novartis AG, Nuevolution AB, Pharmaxis Limited, Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., Respira Therapeutics Inc, Ribomic Inc., Saje Pharma, LLC, Samumed LLC, Sanofi Sorrento Therapeutics, Inc., SPR Biosciences LLC, Teva Pharmaceutical Industries Ltd., Therabron Therapeutics, Inc., Vicore Pharma AB and Yuhan Corporation.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=743476 .
The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 14, 13, 1, 49 and 8 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 3 molecules, respectively for Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Another newly published market research report titled Bronchiectasis - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Alitair Pharmaceuticals, Inc., Bayer AG, Grifols, S.A., Insmed Incorporated, Kamada Ltd., Polyphor Ltd., Raptor Pharmaceutical Corp., Recipharm AB, Savara Inc. and Vertex Pharmaceuticals Incorporated. Bronchiectasis Pipeline market research report of 84 pages is available at http://www.reportsnreports.com/reports/743455-bronchiectasis-pipeline-review-h2-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact: Ritesh Tiwari 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001 Maharashtra, India. Tel: +1-888-391-5441 firstname.lastname@example.org
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Subscribe to our Free Newsletters!